<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39077977</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2578-5745</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>ACR open rheumatology</Title><ISOAbbreviation>ACR Open Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Diffuse Alveolar Hemorrhage With Avacopan.</ArticleTitle><Pagination><StartPage>707</StartPage><EndPage>716</EndPage><MedlinePgn>707-716</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acr2.11726</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Avacopan, an activated complement factor 5 receptor antagonist, has been approved as adjunct therapy for severe active antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Current evidence supports the management of AAV presenting with diffuse alveolar hemorrhage (DAH) by administering glucocorticoids combined with either rituximab or cyclophosphamide in addition to supportive care. The role of avacopan in patients with DAH as a primary severe disease manifestation of AAV has not been well established. Furthermore, concerns remain regarding timely access to avacopan, the best glucocorticoid tapering regimen, and long-term efficacy and safety of the drug. We sought to identify clinical features and outcomes of patients presenting with DAH secondary to AAV who received avacopan in addition to glucocorticoids and rituximab or cyclophosphamide.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study of all consecutive patients presenting with DAH as part of active severe granulomatosis with polyangiitis or microscopic polyangiitis. Demographic and clinical characteristics were collected at presentation and follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifteen patients met inclusion criteria and were observed for a median time of 17 weeks (interquartile range [IQR] 6-37 weeks) after initiation of avacopan. Patients were predominantly female and White, had never smoked, and were a median age of 66 years (IQR 52-72 years) at diagnosis. The majority had newly diagnosed severe AAV with renal involvement. Three patients progressed to respiratory failure. The timing of avacopan introduction and patterns of glucocorticoid tapers varied widely in this cohort. Two serious adverse events related to infection were observed, including one opportunistic infection leading to the patient's death, although neither was directly attributed to avacopan administration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We describe the clinical course of patients who presented with the severe AAV disease manifestation of DAH and received avacopan as adjunct therapy. Most patients achieved remission during follow-up, and adverse events, including infection, were observed.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falde</LastName><ForeName>Sam D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0003-2698-9892</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>Amos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cartin-Ceba</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mayo Clinic Arizona, Scottsdale.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mertz</LastName><ForeName>Lester E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Mayo Clinic Arizona, Scottsdale.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fervenza</LastName><ForeName>Fernando C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zand</LastName><ForeName>Ladan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koster</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-2895-6755</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warrington</LastName><ForeName>Kenneth J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Augustine S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Mayo Clinic Jacksonville, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslam</LastName><ForeName>Nabeel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic Jacksonville, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abril</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mayo Clinic Jacksonville, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Specks</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACR Open Rheumatol</MedlineTA><NlmUniqueID>101740025</NlmUniqueID><ISSNLinking>2578-5745</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>7</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39077977</ArticleId><ArticleId IdType="pmc">PMC11471946</ArticleId><ArticleId IdType="doi">10.1002/acr2.11726</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kitching AR, Anders HJ, Basu N et al. ANCA&#x2010;associated vasculitis. Nat Rev Dis Primers 2020;6(1):71.</Citation><ArticleIdList><ArticleId IdType="pubmed">32855422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimoto Y, Horiuchi T. The complement system and ANCA associated vasculitis in the era of anti&#x2010;complement drugs. Front Immunol 2022;13:926044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260009</ArticleId><ArticleId IdType="pubmed">35812453</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber A, Xiao H, Jennette JC et al. C5a receptor mediates neutrophil activation and ANCA&#x2010;induced glomerulonephritis. J Am Soc Nephrol 2009;20(2):289&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637051</ArticleId><ArticleId IdType="pubmed">19073822</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao H, Dairaghi DJ, Powers JP et al. C5a receptor (CD88) blockade protects against MPO&#x2010;ANCA GN. J Am Soc Nephrol 2014;25(2):225&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904560</ArticleId><ArticleId IdType="pubmed">24179165</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekker P, Dairaghi D, Seitz L et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS One 2016;11(10):e0164646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074546</ArticleId><ArticleId IdType="pubmed">27768695</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DRW, Bruchfeld AN, Harper L et al; CLEAR Study Group . Randomized trial of C5a receptor inhibitor avacopan in ANCA&#x2010;associated vasculitis. J Am Soc Nephrol 2017;28(9):2756&#x2013;2767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576933</ArticleId><ArticleId IdType="pubmed">28400446</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkel PA, Niles J, Jimenez R et al; CLASSIC Investigators . Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody&#x2010;associated vasculitis. ACR Open Rheumatol 2020;2(11):662&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672305</ArticleId><ArticleId IdType="pubmed">33128347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DRW, Merkel PA, Schall TJ et al; ADVOCATE Study Group . Avacopan for the treatment of ANCA&#x2010;associated vasculitis. N Engl J Med 2021;384(7):599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">33596356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmich B, Sanchez&#x2010;Alamo B, Schirmer JH et al. EULAR recommendations for the management of ANCA&#x2010;associated vasculitis: 2022 update. Ann Rheum Dis 2024;83(1):30&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">36927642</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennette JC, Falk RJ, Bacon PA et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23045170</ArticleId></ArticleIdList></Reference><Reference><Citation>Suppiah R, Robson JC, Grayson PC, et al; DCVAS Study Group . 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol 2022;74(3):400&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">35106973</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson JC, Grayson PC, Ponte C, et al; DCVAS Study Group . 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol 2022;74(3):393&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">35106964</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartin&#x2010;Ceba R, Diaz&#x2010;Caballero L, Al&#x2010;Qadi MO et al. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody&#x2010;associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol 2016;68(6):1467&#x2013;1476.</Citation><ArticleIdList><ArticleId IdType="pubmed">26713723</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartuccio L, Bond M, Isola M, et al; Italian Study Group on Lung Involvement in Rheumatic Diseases and the Italian Vasculitis Study Group . Alveolar haemorrhage in ANCA&#x2010;associated vasculitis: long&#x2010;term outcome and mortality predictors. J Autoimmun 2020;108:102397.</Citation><ArticleIdList><ArticleId IdType="pubmed">31926833</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R et al. Research electronic data capture (REDCap)&#x2013;a metadata&#x2010;driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JH, Hoffman GS, Merkel PA et al; International Network for the Study of the Systemic Vasculitides (INSSYS) . A disease&#x2010;specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001;44(4):912&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">11318006</ArticleId></ArticleIdList></Reference><Reference><Citation>
Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events: OHRP Guidance (2007). US Department of Health and Human Services; 2007. Accessed October 2, 2023. https://www.hhs.gov/ohrp/regulations-and-policy/guidance/reviewing-unanticipated-problems/index.html.</Citation></Reference><Reference><Citation>Berti A, Specks U. The survival of patients with alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody&#x2010;associated vasculitis. J Rheumatol 2021;48(3):314&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">34237000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang S, Li X, Zhao KY, et al. Clinical characteristics and prognostic analysis of microscopic polyangiitis with diffuse alveolar hemorrhage. J Rheumatol 2021;48(3):410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">32611666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostianovsky A, Hauser T, Pagnoux C, et al; French Vasculitis Study Group (FVSG) . Alveolar haemorrhage in ANCA&#x2010;associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 2012;30(1 suppl 70):S77&#x2013;S82.</Citation><ArticleIdList><ArticleId IdType="pubmed">22640651</ArticleId></ArticleIdList></Reference><Reference><Citation>Flossmann O, Berden A, Groot Kd, et al; European Vasculitis Study Group . Long&#x2010;term patient survival in ANCA&#x2010;associated vasculitis. Ann Rheum Dis 2011;70(3):488&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">21109517</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez &#xc1;lamo B, Moi L, Bajema I, et al; EUVAS . Long&#x2010;term outcomes and prognostic factors for survival of patients with ANCA&#x2010;associated vasculitis. Nephrol Dial Transplant 2023;38(7):1655&#x2013;1665.</Citation><ArticleIdList><ArticleId IdType="pubmed">36617233</ArticleId></ArticleIdList></Reference><Reference><Citation>Fussner LA, Flores&#x2010;Su&#xe1;rez LF, Cartin&#x2010;Ceba R, et al; PEXIVAS Investigators . Alveolar hemorrhage in antineutrophil cytoplasmic antibody&#x2010;associated vasculitis: results of an international randomized controlled trial (PEXIVAS). Am J Respir Crit Care Med 2024;209(9):1141&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11092964</ArticleId><ArticleId IdType="pubmed">38346237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody&#x2010;associated vasculitis. Arthritis Care Res (Hoboken) 2021;73(8):1088&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">34235880</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 2021;100(4):753&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">34556300</ArticleId></ArticleIdList></Reference><Reference><Citation>Buch MH, Smolen JS, Betteridge N et al; Rituximab Consensus Expert Committee . Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70(6):909&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086093</ArticleId><ArticleId IdType="pubmed">21378402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauci AS, Katz P, Haynes BF et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979;301(5):235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">36563</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M, Merkel PA, Peh CA, et al; PEXIVAS Investigators . Plasma exchange and glucocorticoids in severe ANCA&#x2010;associated vasculitis. N Engl J Med 2020;382(7):622&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325726</ArticleId><ArticleId IdType="pubmed">32053298</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti&#x2010;neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170(1):52&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1762697</ArticleId><ArticleId IdType="pubmed">17200182</ArticleId></ArticleIdList></Reference><Reference><Citation>Henson PM, McCarthy K, Larsen GL, et al. Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol 1979;97(1):93&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2042383</ArticleId><ArticleId IdType="pubmed">495697</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk PN, Scola A&#x2010;M, Madala P, et al. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007;152(4):429&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2050825</ArticleId><ArticleId IdType="pubmed">17603557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu R, Chen ZF, Yan J et al. Complement C5a exacerbates acute lung injury induced through autophagy&#x2010;mediated alveolar macrophage apoptosis. Cell Death Dis 2014;5(7):e1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123068</ArticleId><ArticleId IdType="pubmed">25032853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkia A, Flossmann O, Jones R, et al. Avacopan for ANCA&#x2010;associated vasculitis with hypoxic pulmonary haemorrhage. Nephrol Dial Transplant 2024:gfae020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11361805</ArticleId><ArticleId IdType="pubmed">38268434</ArticleId></ArticleIdList></Reference><Reference><Citation>
TAVNEOS
. Full prescribing information. US Food and Drug Administration; 2021. Accessed November 30, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214487s000lbl.pdf
</Citation></Reference><Reference><Citation>Tesar V, Hruskova Z. Complement inhibition in ANCA&#x2010;associated vasculitis. Front Immunol 2022;13:888816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307875</ArticleId><ArticleId IdType="pubmed">35880179</ArticleId></ArticleIdList></Reference><Reference><Citation>
Merkel P, Hellmich B, Pfaff A, et al. A randomized, double&#x2010;blind, phase II study of glucocorticoid replacement by vilobelimab, an anti&#x2010;C5a monoclonal antibody, in ANCA&#x2010;associated vasculitis [abstract]. Arthritis Rheumatol
2022;74(suppl 9). https://acrabstracts.org/abstract/a&#x2010;randomized&#x2010;double&#x2010;blind&#x2010;phase&#x2010;ii&#x2010;study&#x2010;of&#x2010;glucocorticoid&#x2010;replacement&#x2010;by&#x2010;vilobelimab&#x2010;an&#x2010;anti&#x2010;c5a&#x2010;monoclonal&#x2010;antibody&#x2010;in&#x2010;anca&#x2010;associated&#x2010;vasculitis/
</Citation></Reference><Reference><Citation>Vlaar APJ, Witzenrath M, van Paassen P, et al; PANAMO study group . Anti&#x2010;C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID&#x2010;19 (PANAMO): a multicentre, double&#x2010;blind, randomised, placebo&#x2010;controlled, phase 3 trial. Lancet Respir Med 2022;10(12):1137&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9451499</ArticleId><ArticleId IdType="pubmed">36087611</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvelli J, Meziani F, Dellamonica J, et al; FOR COVID Elimination (FORCE) Study Group . Avdoralimab (anti&#x2010;C5aR1 mAb) versus placebo in patients with severe COVID&#x2010;19: results from a randomized controlled trial (For COVID Elimination [FORCE]). Crit Care Med 2022;50(12):1788&#x2013;1798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9674430</ArticleId><ArticleId IdType="pubmed">36218354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>